CTV News Channel with Dr. Sharon Cohen on FDA approval of Aducanumab

CTV News Channel with Dr. Sharon Cohen on FDA approval of Aducanumab

Dr. Sharon Cohen, Medical Director and Principal Investigator at Toronto Memory Program discusses the exciting news that FDA has approved the use of Aducanumab. The first new treatment for Alzheimer's disease in 20 years and the very first disease-modifying drug proven to slow AD progression.

Latest Tweets

Treatment with Alzheon's oral candidate ALZ-801 lowered levels of a key biomarker for #alzheimersdisease — and led to significant memory ... improvements in people with the neurodegenerative disorder.
https://alzheimersnewstoday.com/news/oral-alz-801-lowers-key-biomarker-trial-may-slow-alzheimers/

What's happening at the forefront of #Alzheimers research? 🧠🔬

In ep. 126 of Eat Move Think, Dr. Lorne Greenspan checks in with our ... clinical dir. of #genetics Jessica Gu and Dr. Sharon Cohen, the medical director at @Toronto_Memory Program.

Listen now: https://eatmovethinkpodcast.com/podcast/ep126-alzheimers-diagnosis-treatment-prevention

Toronto Memory Program

A Headlands Research Company

© 2022 Toronto Memory Program. All rights reserved.